Leveraging virus-free techniques and protocols, the research laboratories of ADSCC created the iPSCs. Credit: Abu Dhabi Stem Cells Center.

The Abu Dhabi Stem Cells Center (ADSCC) in the UAE has developed clinical-grade induced pluripotent stem cells (iPSCs) that meet the good manufacturing practice protocols, marking the ‘first’ in the Middle East.

The ADSCC’s research laboratories created these iPSCs by leveraging virus-free techniques and protocols.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

iPSCs are intended for use in therapeutic applications, including treatments for neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, Parkinson’s, and diabetes. To treat these conditions, ADSCC is actively conducting multiple research projects to explore iPSCs’ use.

They are derived by reprogramming adult cells to an embryonic-like state and can be distinguished into various cell types. This technology allows for personalised therapies from own cells of an individual, reducing the immune rejection risk.

ADSCC’s virus-free protocol avoids genetic modification, which minimises complications such as tumour formation. Its adherence to stringent clinical standards ensures that iPSCs are safe for therapeutic use.

The in-house protocol for the development of iPSCs claims to lay a foundation for upcoming therapeutic applications and biomanufacturing in the country.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADSCC CEO and Capital Organ Regeneration (CORi) research project principal investigator professor Yendry Ventura said: “Developing our own clinical-grade iPSCs using a proprietary, virus-free protocol is a monumental step forward for the UAE and the global medical community.

“This accomplishment not only reinforces Abu Dhabi’s position as a hub for cutting-edge medical research but also opens the door to transformative therapies that can address some of the most complex diseases. The success of this project reflects our commitment to delivering safe, innovative, and personalised solutions to patients worldwide.”

In a move to further iPSC research, ADSCC announced a collaboration with Kyoto University’s Center for iPS Cell Research and Application (CiRA) and Rege Nephro, in December 2023.

The partnership focuses on creating a treatment for diabetes using iPSC-derived pancreatic beta cells. A laboratory has been established at Kyoto University in Japan to facilitate discovery work alongside ADSCC’s Abu Dhabi laboratories.